CorMedix Inc. (CRMD) Board Approves Multi-Year $75M Stock Buyback

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy.

CorMedix Inc. (NASDAQ:CRMD) announced that its board approved a share repurchase program authorizing up to $75 million in common stock buybacks, with the program set to remain in place through December 31, 2027. The company indicated the decision reflects confidence in its balance sheet strength, operating performance, and expected future cash flow generation, while maintaining flexibility to continue investing in internal growth initiatives and potential strategic opportunities. CorMedix expects share repurchases to begin as early as the first quarter of 2026. As of December 31, 2025, the company reported approximately $150 million in cash and cash equivalents and about 79.3 million shares outstanding, providing capacity to execute the program alongside ongoing business and clinical development priorities.

At the end of January, CorMedix Inc. (NASDAQ:CRMD) also saw insider activity, with Executive Vice President and General Manager of Healthcare Janet Dillione selling 10,000 shares for proceeds of $68,800. While modest in absolute dollar terms, the transaction represents a round-lot sale by a senior executive overseeing a core business segment. Such activity is often viewed as part of routine compensation management, though investors typically monitor insider transactions closely in smaller-cap biotech companies.

CorMedix Inc. (NASDAQ:CRMD) is a commercial-stage biopharmaceutical company founded on July 28, 2006, and headquartered in Berkeley Heights, New Jersey. The company focuses on developing and commercializing therapies to prevent and treat infections, with DefenCath targeted at patients undergoing hemodialysis.

While we acknowledge the potential of CRMD as a long term investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.